At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Baricitinib (drug), Placebo (drug)
- How long the study runs
- Study runs about 29 months (dates as stated)
- About the drug or intervention
- Baricitinib — drug: Administered orally · Placebo — drug: Administered orally
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 1 Year to 35 Years
- Who
- All
- Number of participants
- 300
- Started
- 2026-02-05
- Last checked
- 2026-10
Plain English Summary
What is this study?
- • Testing a new treatment for diabetes mellitus, type 1
- • Phase3 - 300 participants
- • The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes
Who can take part?
- • Ages 1 Year to 35 Years
- • Diagnosed with diabetes mellitus, type 1
Where?
- • Aberdeen - Aberdeen Royal Infirmary
- • Birmingham - Queen Elizabeth Hospital Birmingham
- • Birmingham - Birmingham Children's Hospital
- • Bristol - Southmead Hospital
- • +4 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 1 Year - 35 Years
- Who can join: All genders
What the study is looking for
- ✓Have a new diagnosis of type 1 diabetes within 100 days prior to starting study intervention
- ✓Have at least one diabetes-related autoantibody found at screening
- ✓Show signs of remaining beta-cell function
- ✓stimulated (peak or 90 min) C-peptide ≥0.2 nmol/L (0.6 ng/mL) at screening
- ✓Weigh at least 8 kilograms (kg) (18 pounds) at screening
Who cannot take part
- ✗Have any other type of diabetes including gestational
- ✗Have uncontrolled high blood pressure
- ✗Have had a heart attack, heart disease, stroke, or heart failure
- ✗Have a history or high risk of venous thromboembolism, lymphoproliferative disease or cancer
- ✗Have a current or recent clinically serious medical condition or infection
See the full criteria
Where Is This Study? (8 UK sites)
Aberdeen Royal Infirmary
Aberdeen AB25 2ZN, United Kingdom
Queen Elizabeth Hospital Birmingham
Birmingham B15 2TH, United Kingdom
Birmingham Children's Hospital
Birmingham B4 6NH, United Kingdom
Southmead Hospital
Bristol BS10 5NB, United Kingdom
Addenbrooke's Hospital
Cambridge CB2 2QQ, United Kingdom
University Hospital of Wales
Cardiff CF14 4XW, United Kingdom
Churchill Hospital
Oxford OX3 7LE, United Kingdom
Southampton General Hospital
Southampton SO16 6YD, United Kingdom
How to Get in Touch
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Sponsor contactCONTACT
Physicians interested in becoming principal investigators please contact
Sponsor contactCONTACT